DLX5 Antibody - #DF3220

Fig. 3 DLX5 expression analysis and its association with CRC progression. A: Comparison of DLX5 expression levels between CRC tissues and normal tissues based on the TCGA-COAD dataset. B: Kaplan-Meier survival curves for comparison of survival rates between CRC patients with high vs. low DLX5 expression. C: RT-qPCR analysis of DLX5 expression in matched fresh CRC tissues and adjacent normal tissues collected from patients during surgery. D: Comparison of DLX5 expression levels across various CRC cell lines (HCT116, HT-29, LOVO, and SW480) and the control cell line NCM460. E: Gene set enrichment analysis indicated significant enrichment of hypertrophic cardiomyopathy-related genes, the extracellular matrix-receptor interaction pathway, and the TGF-β signaling pathway in CRC patients with high DLX5 expression, thus suggesting the association of these pathways with DLX5 upregulation. F: Pearson’s correlation analysis showed a positive correlation between the expression levels of lncRNA RP11-197K6.1 and DLX5 in CRC tissues. G: Western blotting assays showed a decrease in DLX5 expression following lncRNA RP11-197K6.1 knockdown in HCT116 and SW480 cells (***P 

Figure 3 SHFM1 expression based on online database and clinic samples. (A) Expression profile of SHFM1 in patients with ESCC based on different clinical features. (B) The expression of SHFM1 in ESCC tissues was detected by IHC staining. Images were captured at x400 magnification. (C) Expression of SHFM1 in matched 17 ESCC tissues (T) and the non-tumor tissues (N) was explored by western blotting. Relative expression was analyzed and β-actin was used as a normalization control. Data are presented as the mean ± standard deviation. ns, not significant; **P